Patent: 10,166,244
✉ Email this page to a colleague
Summary for Patent: 10,166,244
Title: | Targeting NC.sub.CA-ATP channel for organ protection following ischemic episode |
Abstract: | The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NC.sub.Ca-ATP channel that is regulated by SUR1. Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example. |
Inventor(s): | Simard; J. Marc (Baltimore, MD) |
Assignee: | University of Maryland, Baltimore (Baltimore, MD) The United States of America as Represented by the Department of Veteran Affairs (Washington, DC) |
Application Number: | 15/369,056 |
Patent Claims: | see list of patent claims |
Details for Patent 10,166,244
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2027-01-12 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2027-01-12 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |